Javidi M A, Zolghadr F, Babashah S, Sadeghizadeh M
Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
Exp Clin Endocrinol Diabetes. 2015 Nov;123(10):632-6. doi: 10.1055/s-0035-1555775. Epub 2015 Jul 15.
One of the major obstacles needed to be overcome before using cell therapy for clinical purposes is the high probability of tumor formation in patients who receive the transplants, as undifferentiated stem cells (SCs) have the potential to form teratomas/teratocarcinoma in xenotransplants. In this study the ability of dendrosomal nanocurcumin (solublized curcumin using a biodegradable non-toxic nano-carrier) to affect undifferentiated/hazardous cell, and hence increasing the safety of cell therapy (particularly in diabetes type I) by mesenchymal stem cells (MSCs) was examined. The results showed that after completion of differentiation of human mesenchymal stem cells (hMSCs) into insulin producing cells (IPCs), the expression level of insulin increases, although there remains a minority of undifferentiated cells which still express nestin (gene which is expressed in progenitor stem cells of IPCs). It indicates the emergence of a heterogeneous population containing undifferentiated and differentiated cells. Furthermore our data demonstrated that the expression level of p53 decreases during differentiation of hMSCs into IPCs which implies a more favorable microenvironment for tumor formation following the transplantation of such a heterogeneous population. After treatment with dendrosomal nanocurcumin, nestin expression eliminated, however no significant effect on the expression and secretion of insulin was observed. Together our data shows that dendrosomal nanocurcumin have the ability to affect residual undifferentiated stem cells after the completion of differentiation of MSCs induced to differentiate into IPCs; while it exerts no significant harmful effect on the survival and function of differentiated cells. With regard to the obtained results in this study, exploiting dendrosomal nanocurcumin, after completion of induced differentiation of stem cells and prior to the transplantation step, can be suggested as a very efficient, safe and cost-effective method to eliminate the residual undifferentiated stem cells in cell therapy practices in order to considerably decrease the risk of tumor development following transplantation.
在将细胞疗法用于临床之前,需要克服的主要障碍之一是接受移植的患者出现肿瘤形成的高概率,因为未分化的干细胞在异种移植中有可能形成畸胎瘤/畸胎癌。在本研究中,检测了树枝状纳米姜黄素(使用可生物降解的无毒纳米载体溶解的姜黄素)影响未分化/有害细胞的能力,从而提高间充质干细胞(MSC)进行细胞治疗(特别是在I型糖尿病中)的安全性。结果表明,人骨髓间充质干细胞(hMSC)分化为胰岛素分泌细胞(IPC)后,胰岛素表达水平升高,尽管仍有少数未分化细胞仍表达巢蛋白(在IPC祖干细胞中表达的基因)。这表明出现了包含未分化和分化细胞的异质群体。此外,我们的数据表明,hMSC向IPC分化过程中p53的表达水平降低,这意味着移植这样的异质群体后肿瘤形成的微环境更有利。用树枝状纳米姜黄素处理后,巢蛋白表达消失,但未观察到对胰岛素表达和分泌的显著影响。我们的数据共同表明,树枝状纳米姜黄素能够在诱导分化为IPC的MSC分化完成后影响残留的未分化干细胞;而它对分化细胞的存活和功能没有显著的有害影响。关于本研究获得的结果,在干细胞诱导分化完成后且在移植步骤之前利用树枝状纳米姜黄素,可以被认为是一种非常有效、安全且经济高效的方法,以消除细胞治疗实践中残留的未分化干细胞,从而显著降低移植后肿瘤发生的风险。